S2k-Leitlinie zum Gebrauch von Präparationen zur lokalen Anwendung auf der Haut (Topika) (2018) Wohlrab J, Staubach P, Augustin M, Eisert L, Huenerbein A, Nast A, Reimann H, et al. Journal article Kutane's plasma-cell-rich Pseudolymphoma in histologically complete Response under combined Immunotherapy with Talimogene laherparepvec (TVEC) and Pembrolizumab (2018) Erdmann M, Sponagl F, Kiesewetter F, Schliep S Conference contribution Neuromuscular Side Effects of Immune Checkpoint Inhibitors (2018) Moreira A, Loquai C, Knauss S, Gutzmer R, Dimitriou F, Meier F, Heppt M, et al. Conference contribution Hyponatremia and Nephritis - Rare Side Effects of Checkpoint Inhibitors in Patients with metastatic Melanoma (2018) Mitzel-Rink H, Hassel J, Berking C, Gutzmer R, Heinzerling L, Majenka P, Meier F, et al. Conference contribution Ex vivo expanded NK Cells from Melanoma Patients receive their Migration in a 3D Model and lyse autologous Melanoma Cells (2018) Rossner S, Czerwinski T, Mark C, Gross S, Karg M, Bosch JJ, Schuler-Thurner B, et al. Conference contribution Influence of previous Radiotherapy on the Success of an immune-oncologic Therapy in metastatic Melanoma - a retrospective multicenter Study of ADO (2018) Knispel S, Zimmer L, Gutzmer R, Heinzerling L, Weishaupt C, Pfoehler C, Gesierich A, et al. Conference contribution Extracellular Vesicles in the Plasma of Melanoma Patients under-press beta Catenin in Tumor Cells by using miRNA-34a (2018) Baur A, Lee JH, Dindorf J, Eberhardt M, Lai X, Ostalecki C, Koliha N, et al. Conference contribution Eosinophilic Fasciitis by Treatment with Checkpoint Inhibitors in metastatic Melanoma (2018) Toussaint F, Erdmann M, Moreira A, Kirchberger MC, Schuler G, Heinzerling L Conference contribution Expression of Senescence Markers - Is Predictive for Immune Therapy with Checkpoint Inhibitors? (2018) Moreira A, Gross S, Kirchberger MC, Erdmann M, Schuler G, Heinzerling L Conference contribution FV03 MEK Inhibitors improved the Survival of NRAS-mutated Melanoma Patients by using Checkpoint Inhibitors: Results of a retrospective, multicenter Analysis of 364 Patients (2018) Kirchberger MC, Ugurel S, Mangana J, Heppt M, Eigentler T, Berking C, Schadendorf D, et al. Conference contribution